{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:59:28Z","timestamp":1762869568984,"version":"3.41.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was funded by the Department of Research Applications and Industrial Relations (DARRI) of Institut Pasteur, Paris, France."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cervical cancer screening programs are increasingly relying on sensitive molecular approaches as primary tests to detect high-risk human papillomaviruses (hrHPV), the causative agents of cervix cancer. Although hrHPV infection is a pre-requisite for the development of most precancerous lesions, the mere detection of viral nucleic acids, also present in transient infections, is not specific of the underlying cellular state, resulting in poor positive predictive values (PPV) regarding lesional states. There is a need to increase the specificity of molecular tests for better stratifying individuals at risk of cancer and to adapt follow-up strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>HPV-RNA-SEQ, a targeted RNA next generation sequencing assay allowing the detection of up to 16 hrHPV splice events and key human transcripts, has previously shown encouraging PPV for the detection of precancerous lesions. Herein, on 302 patients with normal cytology (NILM, <jats:italic>n<\/jats:italic>\u2009=\u2009118), low-grade (LSIL, <jats:italic>n<\/jats:italic>\u2009=\u2009104) or high-grade squamous intraepithelial lesions (HSIL, <jats:italic>n<\/jats:italic>\u2009=\u200980), machine learning-based model improvement was applied to reach 2-classes (NILM vs HSIL) or 3-classes (NILM, LSIL, HSIL) predictive models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Linear (elastic net) and nonlinear (random forest) approaches resulted in five 2-class models that detect HSIL vs NILM in a validation set with specificity up to 0.87, well within the range of PPV of other competing RNA-based tests in a screening population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>HPV-RNA-SEQ improves the detection of HSIL lesions and has the potential to complete and eventually replace current molecular approaches as a first-line test. Further performance evaluation remains to be done on larger and prospective cohorts.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10020-025-01238-x","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T11:55:55Z","timestamp":1748606155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular detection of hrHPV-induced high-grade squamous intraepithelial lesions of the cervix through a targeted RNA next generation sequencing assay"],"prefix":"10.1186","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9790-1583","authenticated-orcid":false,"given":"Julia","family":"Faillace Thiesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-3011","authenticated-orcid":false,"given":"Elise","family":"Jacquemet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Campagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Brochot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-0917","authenticated-orcid":false,"given":"Yves-Edouard","family":"Herpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3675-5013","authenticated-orcid":false,"given":"Nolwenn M.","family":"Dheilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Bouilloux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Rognon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Douablin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-2152","authenticated-orcid":false,"given":"Guillaume","family":"Leboucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Percher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-7207","authenticated-orcid":false,"given":"Marc","family":"Eloit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-8200","authenticated-orcid":false,"given":"Philippe","family":"P\u00e9rot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"1","key":"1238_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12916-022-02386-1","volume":"20","author":"KM Andralojc","year":"2022","unstructured":"Andralojc KM, Elmelik D, Rasing M, Pater B, Siebers AG, Bekkers R, et al. Targeted RNA next generation sequencing analysis of cervical smears can predict the presence of hrHPV-induced cervical lesions. BMC Med. 2022;20(1):206.","journal-title":"BMC Med"},{"issue":"7","key":"1238_CR2","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(22)00294-7","volume":"23","author":"M Arbyn","year":"2022","unstructured":"Arbyn M, Simon M, de Sanjos\u00e9 S, Clarke MA, Poljak M, Rezhake R, et al. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis. Lancet Oncol. 2022;23(7):950\u201360.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1238_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12672-022-00551-9","volume":"13","author":"M Arip","year":"2022","unstructured":"Arip M, Tan LF, Jayaraj R, Abdullah M, Rajagopal M, Selvaraja M. Exploration of biomarkers for the diagnosis, treatment and prognosis of cervical cancer: a review. Discov Oncol. 2022;13(1):91. https:\/\/doi.org\/10.1007\/s12672-022-00551-9.","journal-title":"Discov Oncol."},{"issue":"1","key":"1238_CR4","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1186\/s12885-022-10179-1","volume":"22","author":"MT Bruno","year":"2022","unstructured":"Bruno MT, Cassaro N, Mazza G, Guaita A, Boemi S. Spontaneous regression of cervical intraepithelial neoplasia 3 in women with a biopsy\u2014cone interval of greater than 11 weeks. BMC Cancer. 2022;22(1):1072.","journal-title":"BMC Cancer"},{"key":"1238_CR5","doi-asserted-by":"crossref","unstructured":"Cerasuolo A, Buonaguro L, Buonaguro FM, Tornesello ML. The role of RNA splicing factors in cancer: regulation of viral and human gene expression in human papillomavirus-related cervical cancer. Front Cell Dev Biol. 2020;8. Available from:\u00a0https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2020.00474. Cited 2024 Jan 23.","DOI":"10.3389\/fcell.2020.00474"},{"issue":"462\u2013463","key":"1238_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.virol.2014.05.026","volume":"1","author":"J Chen","year":"2014","unstructured":"Chen J, Xue Y, Poidinger M, Lim T, Chew SH, Pang CL, et al. Mapping of HPV transcripts in four human cervical lesions using RNAseq suggests quantitative rearrangements during carcinogenic progression. Virology. 2014;1(462\u2013463):14\u201324.","journal-title":"Virology"},{"key":"1238_CR7","doi-asserted-by":"crossref","unstructured":"Choi YJ, Lee A, Kim TJ, Jin HT, Seo YB, Park JS, et al. E2\/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma. J Gynecol Oncol. 2018;29(3). Available from: https:\/\/synapse.koreamed.org\/articles\/1093909.\u00a0Cited 2023 Sep 18.","DOI":"10.3802\/jgo.2018.29.e38"},{"issue":"4","key":"1238_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00404-017-4335-7","volume":"295","author":"A Ciavattini","year":"2017","unstructured":"Ciavattini A, Clemente N, Tsiroglou D, Sopracordevole F, Serri M, Delli Carpini G, et al. Follow up in women with biopsy diagnosis of cervical low-grade squamous intraepithelial lesion (LSIL): how long should it be? Arch Gynecol Obstet. 2017;295(4):997\u20131003.","journal-title":"Arch Gynecol Obstet"},{"issue":"87","key":"1238_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jcv.2016.12.004","volume":"1","author":"DA Cook","year":"2017","unstructured":"Cook DA, Smith LW, Law J, Mei W, van Niekerk DJ, Ceballos K, et al. Aptima HPV Assay versus Hybrid Capture\u00ae 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial. J Clin Virol. 2017;1(87):23\u20139.","journal-title":"J Clin Virol"},{"issue":"4","key":"1238_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/bjc.2013.22","volume":"108","author":"J Cuzick","year":"2013","unstructured":"Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108(4):908\u201313.","journal-title":"Br J Cancer"},{"issue":"1","key":"1238_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13027-020-0278-x","volume":"15","author":"A Derbie","year":"2020","unstructured":"Derbie A, Mekonnen D, Woldeamanuel Y, Van Ostade X, Abebe T. HPV E6\/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review. Infect Agent Cancer. 2020;15(1):9.","journal-title":"Infect Agent Cancer"},{"issue":"29","key":"1238_CR12","doi-asserted-by":"publisher","first-page":"e29530","DOI":"10.1097\/MD.0000000000029530","volume":"101","author":"CA Dombrowski","year":"2022","unstructured":"Dombrowski CA, Weston GM, Descamps PP, Izopet PJ, Adams EJ, Adams E. Health economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA HR-HPV assay for the proposed French cervical screening programme. Medicine (Baltimore). 2022;101(29):e29530.","journal-title":"Medicine (Baltimore)"},{"issue":"32","key":"1238_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jcv.2004.12.006","volume":"1","author":"J Doorbar","year":"2005","unstructured":"Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;1(32):7\u201315.","journal-title":"J Clin Virol"},{"issue":"9","key":"1238_CR14","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/jmv.24199","volume":"87","author":"S Duvlis","year":"2015","unstructured":"Duvlis S, Popovska-Jankovic K, Arsova ZS, Memeti S, Popeska Z, Plaseska-Karanfilska D. HPV E6\/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women. J Med Virol. 2015;87(9):1578\u201386.","journal-title":"J Med Virol"},{"issue":"3","key":"1238_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00404-022-06680-4","volume":"307","author":"A Ehret","year":"2023","unstructured":"Ehret A, Bark VN, Mondal A, Fehm TN, Hampl M. Regression rate of high-grade cervical intraepithelial lesions in women younger than 25 years. Arch Gynecol Obstet. 2023;307(3):981\u201390.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"1238_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbagrm.2019.01.001","volume":"1862","author":"D Est\u00eav\u00e3o","year":"2019","unstructured":"Est\u00eav\u00e3o D, Costa NR, da Costa RMG, Medeiros R. Hallmarks of HPV carcinogenesis: The role of E6, E7 and E5 oncoproteins in cellular malignancy. Biochim Biophys Acta BBA-Gene Regul Mech. 2019;1862(2):153\u201362.","journal-title":"Biochim Biophys Acta BBA-Gene Regul Mech"},{"key":"1238_CR17","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Evaluation de la recherche des papillomavirus humains (HPV) en d\u00e9pistage primaire des l\u00e9sions pr\u00e9canc\u00e9reuses et canc\u00e9reuses du col de l\u2019ut\u00e9rus et de la place du double immuno-marquage p16\/Ki67. 2019. Haute Autorit\u00e9 de Sant\u00e9, Saint-Denis, France. https:\/\/www.has-sante.fr\/jcms\/c_2806160\/fr\/evaluation-de-la-recherche-des-papillomavirus-humains-hpv-endepistage-primaire-des-lesions-precancereuses-et-cancereuses-du-col-de-l-uterus-et-de-la-place-du-double-immunomarquage-p16\/ki67"},{"issue":"10","key":"1238_CR18","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1002\/cam4.1501","volume":"7","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7(10):5217\u201336.","journal-title":"Cancer Med"},{"key":"1238_CR19","unstructured":"IARC. Cervical cancer screening. 2022;18. Available from: https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Iarc-Handbooks-Of-Cancer-Prevention\/Cervical-Cancer-Screening-2022. Cited 2025 Mar 10."},{"key":"1238_CR20","doi-asserted-by":"publisher","unstructured":"Iftner T, Neis KJ, Castanon A, Landy R, Holz B, Woll-Herrmann A, et al. Longitudinal clinical performance of the RNA-based Aptima Human Papillomavirus (AHPV) assay in comparison to the DNA-based hybrid capture 2 HPV test in two consecutive screening rounds with a 6-year interval in Germany. J Clin Microbiol. 2019;57(1):https:\/\/doi.org\/10.1128\/jcm.01177-18.","DOI":"10.1128\/jcm.01177-18"},{"issue":"5","key":"1238_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jmoldx.2021.01.016","volume":"23","author":"MK Ivanov","year":"2021","unstructured":"Ivanov MK, Titov SE, Dzyubenko VV, et al. Detection of Cervical Lesions and Cancer in Air-Dried Cytologic Smears by Combined Analysis of mRNA and miRNA Expression Levels. J Mol Diagn. 2021;23(5):541\u2013554. https:\/\/doi.org\/10.1016\/j.jmoldx.2021.01.016.","journal-title":"J Mol Diagn."},{"issue":"4","key":"1238_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41416-020-01153-4","volume":"124","author":"M Kamal","year":"2021","unstructured":"Kamal M, Lameiras S, Deloger M, Morel A, Vacher S, Lecerf C, et al. Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site. Br J Cancer. 2021;124(4):777\u201385.","journal-title":"Br J Cancer"},{"key":"1238_CR23","doi-asserted-by":"publisher","first-page":"6935030","DOI":"10.1155\/2019\/6935030","volume":"2019","author":"ACL Macedo","year":"2019","unstructured":"Macedo ACL, Gon\u00e7alves JCN, Bavaresco DV, Grande AJ, Chiaramonte Silva N, Rosa MI. Accuracy of mRNA HPV tests for triage of precursor lesions and cervical cancer: a systematic review and meta-analysis. J Oncol. 2019;2019:6935030.","journal-title":"J Oncol"},{"issue":"2","key":"1238_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41579-021-00617-5","volume":"20","author":"AA McBride","year":"2022","unstructured":"McBride AA. Human papillomaviruses: diversity, infection and host interactions. Nat Rev Microbiol. 2022;20(2):95\u2013108.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"1238_CR25","doi-asserted-by":"publisher","first-page":"e1006211","DOI":"10.1371\/journal.ppat.1006211","volume":"13","author":"AA McBride","year":"2017","unstructured":"McBride AA, Warburton A. The role of integration in oncogenic progression of HPV-associated cancers. PLoS Pathog. 2017;13(4):e1006211.","journal-title":"PLoS Pathog"},{"issue":"8","key":"1238_CR26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2886","volume":"10","author":"CA Moody","year":"2010","unstructured":"Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550\u201360.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1238_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2018.7464","volume":"320","author":"GS Ogilvie","year":"2018","unstructured":"Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320(1):43\u201352.","journal-title":"JAMA"},{"issue":"6","key":"1238_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jama.2023.13174","volume":"330","author":"RB Perkins","year":"2023","unstructured":"Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical cancer screening: a review. JAMA. 2023;330(6):547\u201358.","journal-title":"JAMA"},{"issue":"5","key":"1238_CR29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jmoldx.2019.04.010","volume":"21","author":"P P\u00e9rot","year":"2019","unstructured":"P\u00e9rot P, Biton A, Marchetta J, Pourcelot AG, Nazac A, Marret H, et al. Broad-range papillomavirus transcriptome as a biomarker of papillomavirus-associated cervical high-grade cytology. J Mol Diagn. 2019;21(5):768\u201381.","journal-title":"J Mol Diagn"},{"issue":"1","key":"1238_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.86","volume":"2","author":"M Schiffman","year":"2016","unstructured":"Schiffman M, Doorbar J, Wentzensen N, de Sanjos\u00e9 S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primer. 2016;2(1):1\u201320.","journal-title":"Nat Rev Dis Primer"},{"issue":"17","key":"1238_CR31","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/jnci\/djg037","volume":"95","author":"NF Schlecht","year":"2003","unstructured":"Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JCM, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. JNCI J Natl Cancer Inst. 2003;95(17):1336\u201343.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"1238_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/1097-0215(20001120)89:6<529::AID-IJC11>3.0.CO;2-G","volume":"89","author":"A Schneider","year":"2000","unstructured":"Schneider A, Hoyer H, Lotz B, Leistritza S, K\u00fchne-Heid R, Nindl I, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer. 2000;89(6):529\u201334.","journal-title":"Int J Cancer"},{"issue":"5","key":"1238_CR33","doi-asserted-by":"publisher","first-page":"511.e1","DOI":"10.1016\/j.ajog.2021.05.038","volume":"225","author":"THR Strang","year":"2021","unstructured":"Strang THR, Gottschlich A, Cook DA, Smith LW, Gondara L, Franco EL, et al. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result. Am J Obstet Gynecol. 2021;225(5):511.e1-511.e7.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1238_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1238_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/aogs.13041","volume":"96","author":"E Virtanen","year":"2017","unstructured":"Virtanen E, Kalliala I, Dyba T, Nieminen P, Auvinen E. Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions. Acta Obstet Gynecol Scand. 2017;96(1):61\u20138.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"16","key":"1238_CR36","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.1128\/JVI.00670-11","volume":"85","author":"X Wang","year":"2011","unstructured":"Wang X, Meyers C, Wang HK, Chow LT, Zheng ZM. Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J Virol. 2011;85(16):8080\u201392.","journal-title":"J Virol"},{"issue":"10451","key":"1238_CR37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","volume":"404","author":"F Wei","year":"2024","unstructured":"Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet Lond Engl. 2024;404(10451):435\u201344.","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"1238_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2050","volume":"7","author":"CBJ Woodman","year":"2007","unstructured":"Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11\u201322.","journal-title":"Nat Rev Cancer"},{"key":"1238_CR39","unstructured":"World Health Organization (WHO). Target product profiles for human papillomavirus screening tests to detect cervical pre-cancer and cancer. 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240100275.\u00a0Cited 2025 Mar 10."},{"issue":"11","key":"1238_CR40","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.2741\/1971","volume":"1","author":"ZM Zheng","year":"2006","unstructured":"Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci J Virtual Libr. 2006;1(11):2286\u2013302.","journal-title":"Front Biosci J Virtual Libr"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01238-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01238-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01238-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T11:56:01Z","timestamp":1748606161000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01238-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01238-x","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cervical smears were collected in the context of routine health care by the Biobanque de Picardie (BRIF N BB-0033\u201300017) at the CHU Amiens-Picardie. Leftover samples were used secondarily for research purposes. No additional samples were taken for this study. The biobank guarantees that the people from whom the biological samples and data came have been informed of the research and on their right of opposition, access or rectification, and have not expressed their opposition to the reuse of their biological samples and their personal data. The processing of personal data follows the rules of the European General Data Protection Regulation (GDPR). A Data Protection Officer (DPO) has been designated for this research. Information about the study has been published on the Health Data Hub () under reference F20220616163142.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants from whom the biological samples and data came have been informed of the research and on their right of opposition, access or rectification, and\u00a0have not expressed their opposition to the reuse of their biological samples and their personal data. The processing of personal data follows the rules of the European General Data Protection Regulation (GDPR, Regulation (EU) 2016\/679).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}